Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M. A. B. D. Plaizier"'
Autor:
P. T. R. Rodrigus, Paul Lips, D. A. K. C. J. M. Huijsmans, O. S. Hoekstra, C. Dragoiescu, J. L.P. Kuijpens, M. A. B. D. Plaizier, Jan Willem Coebergh, J. G. Ribot, Gerrit J.J. Teule, D. J. Kuik
Publikováno v:
Clinical Endocrinology. 58:451-455
Summary BACKGROUND Justification for adjuvant radio-iodine (I-131) therapy in differentiated thyroid cancer (DTC) is purely based on retrospective data. This is true for ablative therapy and even more so for high-dosage adjuvant schedules. Randomized
Autor:
A. R. Jonkhoff, M. A. B. D. Plaizier, G. J. J. Teule, Peter C. Huijgens, Gert J. Ossenkoppele
Publikováno v:
British Journal of Cancer
Gallium-67 (67Ga) accumulates in malignant tissues via the transferrin receptor without need for a monoclonal antibody and emits cytotoxic low-energy electrons. In this study we investigated the feasibility, pharmacokinetics, toxicity and preliminary
Autor:
C, Dragoiescu, O S, Hoekstra, D J, Kuik, P, Lips, M A B D, Plaizier, P T R, Rodrigus, D A K C J M, Huijsmans, J G, Ribot, J, Kuijpens, J W W, Coebergh, G J J, Teule
Publikováno v:
Clinical endocrinology. 58(4)
Justification for adjuvant radio-iodine (I-131) therapy in differentiated thyroid cancer (DTC) is purely based on retrospective data. This is true for ablative therapy and even more so for high-dosage adjuvant schedules. Randomized trials on the latt